In Austria, strong and productive medicines are given ultra-seltene Erkrankung für die Welt

Seit Jahrzehnten has developed and produced a number of pharmaceutical products by Takeda mit Hauptsitz in Japan, an innovative Arzneimittel for patients with seltenes and complex disorders. Nun hat der Wiener Standort des Unternehmens eine merksswerte Erfolgsgeschichte zu erzählen: A new Medication for an ultra-seltene Krankheit was developed in Austria and would be produced for the Weltmarkt in Wien.

Research and production in Austria

The innovative Arzneimittel wurde am Standort in Österreich erforscht. Erfolgreich has conducted its clinical trials in eleven states, in Austria, Japan and the USA. With the Leistung between the Austrian Standort of Takeda seine Fahigkeit, high Medikamente complex to wick and rezustellen.

Manfred Rieger, Geschäftsführer und Standortleiter des Research und Entwicklungsbereiches von Takeda in Österreich, erläutert: „The Zulassung dieses Medikaments unterstreicht de bedeutende Rolle unserer österreichischen Innerhalb des globalen Research und Entwicklungsnetzwerks von Takeda. Your involvement and your expertise were separated from that inheritance and Zeigen, whoever any local innovation and merger were. This Errungenschaft celebrates Austria’s position as a central position for research and development at Takeda and brings us a healthy life, the health of the patient with ultra-selective benefits and well-being.”

Since August is the last month, we are happy to welcome you in Japan and the USA, as well as for patients in the European Union and support for affected people in Austria for relief. If you are engaged in the treatment of new therapies from Takeda in Austria, you can try this innovative therapy in an unusual way. If it’s a good idea, patients are well off with lifetime guarantees on their care.

University Prof. Private Doz. Dr. Cihan Ay, Professor of the Federal Hämatology at the Medical Universität Wien, explains: “The research into therapy for the development of normal illness, for all treatment interventions, has a long history in Austria. Take a look at the development and production of such an innovative Arzneimittel einen wichtigen Beitrag and verleiht dem Production standort Österreich weltweit Ansehen. There are eight patients in the east of the country working at the ultra-selected erkrankung cTTP who are affected and one of the few who are in treatment with the new Arzneimittel. In this area, the treatment of Austria has begun according to the Gestaltung of new therapies in medicine throughout Europe and in the whole world.”

Innovative Europe

Takeda’s innovation power has a positive impact on Europe from: Europe is one of the leading companies for the research, development and production of medicines that have a very high value. During the Covid crisis, it became clear that it is essential to produce medicines in Europe. For all people with a selection of illnesses, it is separate, fast and easy to come to a life-changing medicine. It is the best choice that is made in Europe and a production method is offered. The Takeda location in Vienna has an abermal character, which is in the low world, a highly specialized Mediterranean offer at world market level and a certain degree of commitment to global health care for your life.

A medicine for patients*in the world

For the continuous care of patients*in the world by the Arzneimittel in Vienna produces. In Notfällen is the Wiener Standort in the Low, within the Hours Life-Saving-Shipments of the Medicines of People, who require a medical care, through time. So Takeda could lead his life to a new birth in Great Britain, so that he can get a foreign wife and an unborn child in the Swiss region. Reibungslose Lieferketten begin a schnelle Behandlung of Patients*innen in over 100 Ländern worldwide. The life-saving shipments that result in the involvement are caused by the human health by the excellence of the Wiener teams.

Maria Löflund, Vorstandsmitglied von Takeda in Österreich und Leiterin der Takeda Produktionsstandorte in Wien, concretet: “Der Standort Wien is een inzigartiges Beispiel für Innovation, that has abdecken all Schritte von der Schritte von der Schung over the Entwicklung bis its production for the Weltmarkt. We have been producing for over 70 years with healthy medicine in Vienna and have extensive expertise. Am Wiener Standort was restored after 20 different Arzneimittel. Because it is so difficult, our gemstones in Österreich are a product of the Medikamente Menschenleben and are of good quality.”

Rebecca Fowler, Managing Director of Takeda Pharma Austria, said: “It is our mission, a new and innovative medicine that has the diseases in it. So if you help people in the world, you can use the medical treatment of our medicines. True to our motto: ‘better health, better future’ is an innovative therapy, that saves life and improves life quality.’

About the medicine

Takeda’s new drug is the healthiest combination of ADAMTS13 protein with the treatment of congenital thrombotic-thrombozytopenic purpura (cTTP) with the disease, the risks for blood clotting in affected patients* by ringing. The biological Arzneimittel could fall into the acute when a prophylactic therapy is used.

About the disease

Congenital thrombotic thrombocytopenic purpura (cTTP) is an ultra-selten, anborn, chronic blutgerinnungsstörung, which is sold by a mangle of the ADAMTS13 enzymes.

The entered cTTP percentage is at a new ranking for a million people. Without treatment cTTP can be caused by blood clotting of severe complications such as kidney failure, sphincter and heart failure. The mortality rate at a value of TTP-Ereignissen is untreatable at over 90 percent.

About Takeda

Takeda is a prosperous, value-driven, sustainable biopharmaceutical company headquartered in Japan. Takeda has set itself the goal of transforming life-enhancing and life-sustaining medicines into production for the management of rare and complex illnesses. I am a good care for the care of patients, for those or now no longer care for the treatment of patients. At Takeda, we are concerned with patient engagement, care and care in the hospital. https://www.takeda.com

About Takeda in Austria

In Austria you will find a process for innovative Arzneimittel-statt at Takeda: from Research & Entwicklung, über Plasmaaufbringung and production to the care of the patients*. Rund 4,500 Mitarbeiter*innen targen dazu bei, dass Medikamente aus Österreich in über 100 Länder weltweit gelangen and Patient*innen in Österreich Zugang zu de innovative Arzneimitteln von Takeda erhalten. The Austrian product portfolio includes patients in the areas of oncology, seltene metabolic diseases, gastroenterology and immunology. Takeda operates as a certified Top Employer for its comprehensive Employee Experience and its commitment to integration and is an example of sustainable and responsible production. https://www.takeda.at

Press photos:
http://www.publichealth.at/portfolio-items/in-oesterreich-erforschtes-und-produziertes-medikament